WO2007009699A3 - Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases - Google Patents

Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases Download PDF

Info

Publication number
WO2007009699A3
WO2007009699A3 PCT/EP2006/006973 EP2006006973W WO2007009699A3 WO 2007009699 A3 WO2007009699 A3 WO 2007009699A3 EP 2006006973 W EP2006006973 W EP 2006006973W WO 2007009699 A3 WO2007009699 A3 WO 2007009699A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
treatment
pyrazoline compounds
substituted pyrazoline
associated diseases
Prior art date
Application number
PCT/EP2006/006973
Other languages
French (fr)
Other versions
WO2007009699A2 (en
Inventor
Helmut H Buschmann
Original Assignee
Esteve Labor Dr
Helmut H Buschmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384024A external-priority patent/EP1743642A1/en
Application filed by Esteve Labor Dr, Helmut H Buschmann filed Critical Esteve Labor Dr
Publication of WO2007009699A2 publication Critical patent/WO2007009699A2/en
Publication of WO2007009699A3 publication Critical patent/WO2007009699A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of substituted pyrazoline compounds, their derivatives as well as their physiologically acceptable salts, in medicinal products for human therapeutics and/or animal research for the treatment of a variety of diseases associated the cannabinoid receptor system in humans and animals.
PCT/EP2006/006973 2005-07-15 2006-07-15 Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases WO2007009699A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05384024.5 2005-07-15
EP05384024A EP1743642A1 (en) 2005-07-15 2005-07-15 Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
US70547305P 2005-08-05 2005-08-05
US60/705,473 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007009699A2 WO2007009699A2 (en) 2007-01-25
WO2007009699A3 true WO2007009699A3 (en) 2007-04-26

Family

ID=37669158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006973 WO2007009699A2 (en) 2005-07-15 2006-07-15 Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases

Country Status (1)

Country Link
WO (1) WO2007009699A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2042175A1 (en) * 2007-09-21 2009-04-01 Laboratorios del Dr. Esteve S.A. Dose regimens of CB1-Receptor ligands in the treatment of obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083171A1 (en) * 1998-05-29 2001-03-14 Laboratorios Del Dr. Esteve, S.A. Pyrazoline derivatives, their preparation and application as medicaments
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083171A1 (en) * 1998-05-29 2001-03-14 Laboratorios Del Dr. Esteve, S.A. Pyrazoline derivatives, their preparation and application as medicaments
EP1384477A1 (en) * 2001-04-06 2004-01-28 Laboratorios Del Dr. Esteve, S.A. Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Also Published As

Publication number Publication date
WO2007009699A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2008012470A3 (en) Substituted imidazolone derivatives, preparation and uses
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
ATE453642T1 (en) SUBSTITUTED PHENYLAMINOPYRIMIDINES
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
WO2008016811A3 (en) Aminopiperidines and realted compounds
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
WO2007016496A3 (en) Dipiperazinyl ketones and related analogues
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
WO2006009789A3 (en) Aryl-substituted piperazine derivatives
WO2007146122A3 (en) Tetrahydropyrido[3,4-d]pyrimidines and related analogues
TW200611695A (en) Pyrrolopyridine derivatives
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
GB0606805D0 (en) Organic compounds
WO2007118963A3 (en) Substituted n-(phenethyl)benzamide derivatives, preparation and uses thereof
WO2008087366A3 (en) Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2009053628A3 (en) Novel compounds, preparation and uses thereof
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
WO2007025229A3 (en) Compositions and their uses directed to hsp27
WO2007009699A3 (en) Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1743642A8 (en) Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06776265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06776265

Country of ref document: EP

Kind code of ref document: A2